HENGRUI PHARMA: 2025 THIRD QUARTERLY REPORT

Hengrui Pharma announced its Q3 2025 earnings report. In the third quarter, the company achieved operating revenue of RMB 7.427 billion, representing a year-on-year increase of 12.72%; net profit attributable to shareholders of the listed company was RMB 1.301 billion, a year-on-year increase of 9.53%; basic earnings per share were RMB 0.20. Net cash flow from operating activities reached RMB 4.810 billion, a significant year-on-year increase of 209.78%.For the first three quarters, cumulative operating revenue amounted to RMB 23.188 billion, a year-on-year increase of 14.85%; net profit attributable to shareholders of the listed company was RMB 5.751 billion, a year-on-year increase of 24.50%; basic earnings per share were RMB 0.89, up 21.92% year-on-year. Net cash flow from operating activities was RMB 9.110 billion...Show More

Hengrui Pharma announced its Q3 2025 earnings report. In the third quarter, the company achieved operating revenue of RMB 7.427 billion, representing a year-on-year increase of 12.72%; net profit attributable to shareholders of the listed company was RMB 1.301 billion, a year-on-year increase of 9.53%; basic earnings per share were RMB 0.20. Net cash flow from operating activities reached RMB 4.810 billion, a significant year-on-year increase of 209.78%.For the first three quarters, cumulative operating revenue amounted to RMB 23.188 billion, a year-on-year increase of 14.85%; net profit attributable to shareholders of the listed company was RMB 5.751 billion, a year-on-year increase of 24.50%; basic earnings per share were RMB 0.89, up 21.92% year-on-year. Net cash flow from operating activities was RMB 9.110 billion, a year-on-year increase of 98.68%.As of the end of the reporting period, total assets stood at RMB 68.328 billion, an increase pagainst the end of 2023 by 36.29%; owners' equity attributable to shareholders of the listed company was RMB 59.504 billion, up 30.72% against the end of 2023. The growth in asset size is primarily due to the issuance of H shares and an increase in cash received from overseas licensing agreements.